AngioDynamics’ (ANGO) “Buy” Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of AngioDynamics (NASDAQ:ANGO) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $20.00 target price on the medical instruments supplier’s stock.

Other analysts also recently issued research reports about the stock. Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. HC Wainwright boosted their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Zacks Research upgraded shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.50.

AngioDynamics Price Performance

AngioDynamics stock opened at $11.52 on Friday. AngioDynamics has a one year low of $9.39 and a one year high of $16.29. The business’s fifty day moving average is $15.32 and its 200 day moving average is $13.12. The stock has a market capitalization of $484.42 million, a PE ratio of -14.77 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. The company had revenue of $80.92 million during the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, sell-side analysts expect that AngioDynamics will post -0.25 EPS for the current fiscal year.

Insider Activity

In related news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares of the company’s stock, valued at $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 6.00% of the stock is currently owned by company insiders.

Institutional Trading of AngioDynamics

Hedge funds have recently bought and sold shares of the company. Integrated Wealth Concepts LLC bought a new stake in shares of AngioDynamics during the 2nd quarter valued at about $38,000. Legal & General Group Plc bought a new position in shares of AngioDynamics in the 2nd quarter worth approximately $45,000. Public Employees Retirement System of Ohio bought a new position in shares of AngioDynamics in the 2nd quarter worth approximately $64,000. State of Wyoming bought a new position in shares of AngioDynamics in the 2nd quarter worth approximately $72,000. Finally, Inceptionr LLC bought a new position in shares of AngioDynamics in the 1st quarter worth approximately $115,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics News Roundup

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Adjusted earnings beat expectations. AngioDynamics reported fiscal Q1 2027 adjusted EPS of a $0.04 loss, better than the $0.11 loss analysts expected. Revenue reached $80.9 million, slightly above consensus and up 6.9% year over year. Zacks earnings report
• Positive Sentiment: Med Tech growth and margins were strong. Med Tech sales rose 13.2% to $39.9 million, led by 14.7% growth in Auryon sales and 29% growth in NanoKnife sales. Gross margin expanded 410 basis points to 59.4%, while the GAAP net loss narrowed from the prior year. The company also received FDA IDE approval for a NanoKnife feasibility study in benign prostatic hyperplasia. AngioDynamics fiscal Q1 results
• Positive Sentiment: Canaccord reaffirmed its Buy rating and set a $20 price target, implying substantial potential upside from the referenced share price. Benzinga report
• Neutral Sentiment: Fiscal 2027 guidance was reiterated: revenue of $336 million to $341 million and an adjusted EPS loss of $0.24 to $0.29. The outlook remains broadly in line with analyst expectations, but it does not yet indicate a return to profitability. Seeking Alpha guidance report
• Negative Sentiment: Leadership uncertainty is weighing on sentiment. Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The transition adds execution risk even as operating momentum improves. CEO appointment announcement
• Negative Sentiment: Profitability and cash flow remain concerns. AngioDynamics posted a GAAP net loss of $7.1 million and used $15.3 million of operating cash during the quarter. These issues likely overshadowed the adjusted EPS and revenue beats. Reported short-interest data showing zero shares appears inconsistent and should be treated cautiously.

About AngioDynamics

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.